Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

被引：0
|
作者：
Alexander Stein
Albrecht Kretzschmar
Dirk Behringer
Thomas Wolff
Joachim Zimber
Susanna Hegewisch-Becker
Erika Kettner
Karl-Heinz Pflüger
Andreas Kirsch
Dirk Arnold
机构：
[1] University Medical Center,
[2] Hamburg-Eppendorf,undefined
[3] Krankenhaus St Georg,undefined
[4] Augusta-Kranken-Anstalt,undefined
[5] Praxis Lerchenfeld,undefined
[6] Praxis,undefined
[7] Onkologische Schwerpunktpraxis Eppendorf,undefined
[8] University of Magdeburg,undefined
[9] Evangelisches Diakonie-Krankenhaus gGmbH,undefined
[10] Praxis Oskar Helene Heim,undefined
[11] Tumor Biology Center Freiburg,undefined
来源：
BMC Cancer | / 13卷
关键词：
Non-resectable; Metastatic; Colorectal cancer; Capecitabine; Bevacizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Predictors of outcome in elderly patients with metastatic colorectal cancer: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment
    Omrcen, Tomislav
    Katic, Andrija
    Tomic, Snjezana
    Eterovic, Davor
    Vrdoljak, Eduard
    [J]. ANTI-CANCER DRUGS, 2020, 31 (05) : 518 - 522
  • [22] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
    Stein, Alexander
    Binder, Mascha
    Al-Batran, Salah-Eddin
    Hinke, Axel
    Waberer, Lisa
    Goekkurt, Eray
    Meyer, Tobias
    Statovci, Donjete
    Depenbusch, Reinhard
    Riera-Knorrenschild, Jorge
    Lorenzen, Sylvie
    Ettrich, Thomas Jens
    Doerfel, Steffen
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Phase II Trial of Erlotinib and Capecitabine for Patients with Previously Untreated Metastatic Colorectal Cancer
    Kozuch, Peter
    Malamud, Steve
    Wasserman, Carrie
    Homel, Peter
    Mirzoyev, Takhir
    Grossbard, Michael
    [J]. CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 38 - 42
  • [24] Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial
    Giessen, Clemens Albrecht
    Modest, Dominik Paul
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Spaeth-Schwalbe, Ernst
    Freiberg-Richter, Jens
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Peuser, Bettina
    Heinemann, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Clemens Giessen
    Ludwig Fischer von Weikersthal
    Axel Hinke
    Sebastian Stintzing
    Frank Kullmann
    Ursula Vehling-Kaiser
    Julia Mayerle
    Markus Bangerter
    Claudio Denzlinger
    Markus Sieber
    Christian Teschendorf
    Jens Freiberg-Richter
    Christoph Schulz
    Dominik Paul Modest
    Nicolas Moosmann
    Philipp Aubele
    Volker Heinemann
    [J]. BMC Cancer, 11
  • [26] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Giessen, Clemens
    von Weikersthal, Ludwig Fischer
    Hinke, Axel
    Stintzing, Sebastian
    Kullmann, Frank
    Vehling-Kaiser, Ursula
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Freiberg-Richter, Jens
    Schulz, Christoph
    Modest, Dominik Paul
    Moosmann, Nicolas
    Aubele, Philipp
    Heinemann, Volker
    [J]. BMC CANCER, 2011, 11
  • [27] Final results of the randomized phase II VOLFI trial (AIO-KRK0109): mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first line treatment in patients with RAS wild -type metastatic colorectal cancer (mCRC)
    Geissler, M.
    Tannapfel, A.
    Reinacher-Schick, A.
    Martens, U.
    Ricke, J.
    Riera-Knorrenschield, J.
    Kanzler, S.
    Held, S.
    Heinemann, V.
    Seufferlein, T.
    Modest, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [28] THE TEX REGIMEN (DOCETAXEL, OXALIPLATIN AND CAPECITABINE) IN PATIENTS WITH ADVANCED OR METASTATIC GASTRIC AND GASTROESOPHAGEAL CANCER: RESULTS FROM A PHASE II TRIAL OF THE GERMAN AIO GROUP
    Thuss-Patience, P.
    Arnold, D.
    Stein, A.
    Grothe, W.
    Seufferlein, T.
    Reinacher-Schick, A.
    Geissler, M.
    Hofheinz, R.
    Moehler, M.
    Schmoll, H.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 90 - 90
  • [29] Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer
    Amin, Manik
    Desai, Monica
    Trinkaus, Kathryn
    Brown, Amberly
    Wang-Gillam, Andrea
    Tan, Benjamin
    Picus, Joel
    Sorscher, Steven
    Highkin, Maureen
    Lears, Kim
    Lockhart, Albert C.
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (03) : 412 - 420
  • [30] Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
    Hans-Joachim Schmoll
    Julia Mann
    Fabian Meinert
    Benjamin Garlipp
    Kersten Borchert
    Arndt Vogel
    Eray Goekkurt
    Ulrich Kaiser
    Heinz-Gert Hoeffkes
    Jörn Rüssel
    Stephan Kanzler
    Thomas Edelmann
    Helmut Forstbauer
    Thomas Göhler
    Carla Hannig
    Bert Hildebrandt
    Carsten Roll
    Carsten Bokemeyer
    Jörg Steighardt
    Franziska Cygon
    Stefan Ibach
    Alexander Stein
    Joseph Tintelnot
    [J]. British Journal of Cancer, 2024, 130 : 233 - 241
12345